Compare · JNJ vs PROC
JNJ vs PROC
Side-by-side comparison of Johnson & Johnson (JNJ) and Procaps Group S.A. (PROC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and PROC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $634.06B, about 602.3x PROC ($1.05B).
- JNJ has hit the wire 12 times in the past 4 weeks while PROC has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for PROC).
- Company
- Johnson & Johnson
- Procaps Group S.A.
- Price
- $263.42+1.56%
- $1.16-27.50%
- Market cap
- $634.06B
- $1.05B
- 1M return
- +9.30%
- -
- 1Y return
- +58.48%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Procaps Group S.A.
Procaps Group, S.A. develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and clinical solutions. It operates in 13 countries in Latin America. The company was founded in 1977 and is based in Luxembourg City, Luxembourg
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
- Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
- EVP, Global Corp Affairs Broadhurst Vanessa exercised 23,054 shares at a strike of $130.77 and sold $5,792,686 worth of shares (23,054 units at $251.27) (SEC Form 4)
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates
- Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
- DePuy Synthes Acquires Expanding Innovations™
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
Latest PROC
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Receives Delisting Notice From Nasdaq
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Receives Additional Delinquency Letter
- SEC Form 6-K filed by Procaps Group S.A.
- SEC Form 6-K filed by Procaps Group S.A.
- Procaps Group Announces Key Shareholder and Board Decisions, Committee Restructuring, and Leadership Updates
- Amendment: SEC Form SC 13D/A filed by Procaps Group S.A.